ALLMedicine™ Bacterial Conjunctivitis Center
Research & Reviews 261 results
JAMA Ophthalmology; Sun H, Temeck JW et. al.
Dec 17th, 2020 - Off-label treatment was common for ophthalmia neonatorum because only erythromycin ointment had been approved by the US Food and Drug Administration (FDA) for this indication. Ophthalmia neonatorum was previously considered a different indication ...
The Journal of Dermatology; Ajima S, Sano Y et. al.
Oct 28th, 2020 - Ophthalmic quinolone preparations are widely used for the treatment of eye diseases; however, there are only a few reported cases of immediate hypersensitivity due to such medications. Here, we present a case of immediate hypersensitivity induced ...
PloS One; DeCory HH, Sanfilippo CM et. al.
Aug 25th, 2020 - To date, studies examining polymicrobial infections in ocular disease have mostly been limited to keratitis or endophthalmitis. We characterized polybacterial infections compared to monobacterial infections in prior clinical studies evaluating bes...
International Journal of Nanomedicine; Alruwaili NK, Zafar A et. al.
Jul 8th, 2020 - The present study was designed to study the gentamycin (GTM)-loaded stimulus-responsive chitosan nanoparticles to treat bacterial conjunctivitis. GTM-loaded chitosan nanoparticles (GTM-CHNPs) were prepared by ionotropic gelation method and further...
The Journal of Adolescent Health : Official Publication O... Chavis A, Bakken H et. al.
Jun 30th, 2020 - The novel coronavirus disease-2019 (COVID-19) was declared a pandemic by the World Health Organization on March 11, 2020. We discuss a less common presentation of COVID-19 in a patient where the use of telemedicine technology prevented the exposur...
Guidelines 1 results
Nov 12th, 2018 - Evidence-based update using Cochrane Eyes and Vision Group-identified systematic reviews for the initial evaluation of conjunctivitis patients and discussion of associated or predisposing factors.
Drugs 147 results see all →
Clinicaltrials.gov 425 results
Feb 21st, 2021 - BESIVANCE ® (besifloxacin ophthalmic suspension) 0.6%, is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans* CDC coryneform group G Corynebacterium pseudodiphtheri...
Feb 11th, 2021 - Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following mic...
Feb 7th, 2021 - Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium speciesEfficacy for this organism was studied in fewer than 10 infections. Microc...
Feb 2nd, 2021 - Gatifloxacin ophthalmic solution, 0.5% is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epi...
Jan 17th, 2021 - Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following mic...
News 13 results
Kevin Bryan Uy Lo, MD, Zurab Azmaiparashvili, MD
Dec 2nd, 2019 - A 66-year-old man presented with burning pain and erythema over the left axilla, and pustules that had ruptured and crusted over. The rash also involved the right axilla, trunk, abdomen, and face.
McKenzie Momany, Douglas Paauw, MD, MACP
Sep 20th, 2019 - A 54-year-old pharmacist with a history of gout, hypertension, and conjunctivitis presents for evaluation of pink eye in the summer. The morning before coming into the office, he noticed that his right eye was red and inflamed.
Jun 22nd, 2017 - Antibiotic eye drops cannot treat most pinkeye cases, reported The New York Times. A recent study looked at over 300,000 people diagnosed with pinkeye and found that over 58% were prescribed antibiotics, even though they only work 20% of the time,...
May 23rd, 2010 - May 24, 2010 — The US Food and Drug Administration (FDA) has approved gatifloxacin 0.5% ophthalmic solution (Zymaxid; Allergan, Inc) for the treatment of bacterial conjunctivitis caused by susceptible strains of Haemophilus influenzae, Staphylococ...
May 28th, 2009 - WASHINGTON, May 28 -- The FDA has approved besifloxacin ophthalmic suspension 0.6% (Besivance) for the treatment of bacterial conjunctivitis. The drug is a novel fluoroquinolone antibiotic found to inhibit production of proinflammatory cytokines i...